Generation bio reports business highlights and fourth quarter and full year 2023 financial results

- company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia

GBIO Ratings Summary

GBIO Quant Ranking